Like we always do about this time of year, FierceBiotech is kicking off its search for the next class of Fierce 15 companies, and we want to hear from you. It's easy: Just fill out the form embedded below or find it here.
We're looking for the brightest and bravest among private biotechs, and reader nominations complement our research, interviews and debates in assembling the list each year.
Over more than a decade of Fierce 15 reports, we've seen winners find themselves the targets of 10-figure buyouts, like 2011's Pearl Therapeutics, and become the subjects of high-dollar IPOs, like last year's Foundation Medicine ($FMI). Others, like 2005 alumni Wilex and Ikaria, have had a rougher go of things. And, in keeping with the nature of biotech, some no longer exist. Get the scoop on 2013's winners here.
Now we want to hear from you on which companies should be next on our roster of the most promising drug developers and platform biotechs. The online form is the best way to submit a nomination, but we also welcome suggestions via email or Twitter using the tag #Fierce15. We'll reveal the winners at 2014's BioPharm America conference in September.
Here are the qualifications for consideration:
- Companies must be privately held, not publicly traded.
- Companies should be working on treatments for human diseases. This is not a list of agricultural bio or biofuel ventures.
- Company executives have to be available for interviews and agree to keep their status in our selection process confidential until the final list is announced.
And that's about it. We don't discriminate by disease area, therapeutic modality or country of origin--in fact, we'd love to see our first winner from outside the U.S. and Europe.
Take this opportunity to chime in and tell us what makes your nominee worthy of the Fierce 15.
-- Damian Garde (email | Twitter)